Progress in the application of omalizumab in the treatment of chronic inducible urticaria

Chronic inducible urticaria (CIndU) is a chronic urticaria caused by unique triggers, manifested by wheals and angioedema as common symptoms. Omalizumab is a recombinant humanized anti-IgE antibody, which is currently listed as the third-line treatment for CIndU in international guidelines, and there are some precedents for the treatment of CIndU with omalizumab, but the relevant dose, efficacy, adverse reactions and other data are relatively insufficient. The purpose of this article is to review the efficacy and treatment progress of omalizumab in the treatment of various types of CIndU, and to provide a rationale for the treatment of patients with CIndU.